Large Variation in Provincial Guidelines for Urine Drug Screening During Opioid Agonist Treatment in Canada
Files in This Item:
|UDS editorial edited_Feb14.pdf||126.96 kB||Adobe PDF||Download Request a copy|
|Title:||Large Variation in Provincial Guidelines for Urine Drug Screening During Opioid Agonist Treatment in Canada||Authors:||Moss, Eloise
|Permanent link:||http://hdl.handle.net/10197/10074||Date:||Jun-2018||Online since:||2019-04-23T11:03:16Z||Abstract:||Urine drug screening (UDS) is commonly used to detect or validate self-reported substance use, particularly when beginning and maintaining opioid agonist therapy. However, there is currently no summary of the published clinical practice guidelines for UDS in Canada, and no measure of the consistency with which different provinces suggest administering UDS. Therefore, we conducted a policy scan of UDS guidelines, examining the published clinical practice guidelines for each Canadian province and extracting all relevant data in March 2017. Our Canadian guideline and policy scan found that UDS frequency recommendations vary greatly among Provinces for persons receiving opioid agonist therapy for opioid use disorder.||Type of material:||Journal Article||Publisher:||Wolters Klumer||Journal:||Canadian Journal of Addiction||Volume:||9||Issue:||2||Start page:||6||End page:||9||Copyright (published version):||2018 by Lippincott Williams & Wilkins||Keywords:||Guidelines; Opioid agonist therapy; Canadian guideline and policy scan; Urine drug screening||DOI:||10.1097/CXA.0000000000000015||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Medicine Research Collection|
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.